Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05280366 · ClinicalTrials.gov registry record · NA

STREAMLINE®SURGICAL SYSTEM Compared to iStent Inject W® in Patients With Open-Angle Glaucoma

A NA study of Open Angle Glaucoma, sponsored by New World Medical.

Active
Registry status
NA
Development phase
150
Enrollment target
20
Study locations

NCT05280366: Active NA study of Open Angle Glaucoma, sponsored by New World Medical.

NCT05280366 is a NA study of Open Angle Glaucoma that is active but no longer recruiting, run by New World Medical. The registered enrollment target is 150 participants, below the 329-participant average among 28 other Open Angle Glaucoma trials with a reported enrollment target (54% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05280366, a NA study of Open Angle Glaucoma, is active but no longer recruiting, sponsored by New World Medical.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
150 participants
Enrollment target
20
Study locations

Study Summary

A study of the Streamline Surgical System versus competitor

Conditions Studied

Interventions

  • DEVICE Streamline Surgical System
  • DEVICE iStent Inject W

Study Locations (20)

Texas

  • Ophthalmology Associates - Fort Worth
  • Berkely Eye Center - Houston
  • R & R Eye Research - San Antonio

California

  • Visionary Research Institute - Newport Beach
  • Wolstan and Goldberg Eye Associates - Torrance

New Jersey

  • Eye Associates of North New Jersey - Dover
  • Eye Associates Surgical Center - Vineland

Other

  • Clinica 20/20 - San José
  • Clinica Laser y Ultrasonido Ocular - Puebla City

Arkansas

  • Vold Vision - Fayetteville

Colorado

  • University of Colorado - Aurora

Florida

  • Ocala Eye - Ocala

Georgia

  • Georgia Eye Partners - Atlanta

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2022-02-09
Est. Completion 2026-06-30
Phase NA
New World Medical

2 total trials

What the registry record for NCT05280366 still lists

NCT05280366 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 329-participant average among 28 other Open Angle Glaucoma trials with a reported enrollment target (54% lower).

The record links to 1 condition, with Open Angle Glaucoma appearing as the primary indexed condition, and to 2 interventions - of which Streamline Surgical System is the first listed.

NCT05280366 names 20 study sites across 15 states, led by Texas, California, New Jersey.

Frequently Asked Questions

What is clinical trial NCT05280366 about?

NCT05280366 is a clinical study titled "STREAMLINE®SURGICAL SYSTEM Compared to iStent Inject W® in Patients With Open-Angle Glaucoma". A study of the Streamline Surgical System versus competitor

What is the current status of trial NCT05280366?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2022-02-09. Estimated completion is 2026-06-30.

What conditions does trial NCT05280366 study?

This clinical trial studies the following conditions: Open Angle Glaucoma.

What interventions are being tested in trial NCT05280366?

The interventions under investigation include: Streamline Surgical System (DEVICE), iStent Inject W (DEVICE).

Who is sponsoring clinical trial NCT05280366?

This trial is sponsored by New World Medical, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05280366 being conducted?

This trial has 20 study locations across Arkansas, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Open Angle Glaucoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05280366's enrollment target sits among peer trials

150 15th of 28 higher than 14 of 28 other Open Angle Glaucoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Open Angle Glaucoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00412594 · 150 participants · Phase 2

    Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

  • NCT01484730 · 150 participants

    A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion

  • NCT01985919 · 150 participants

    Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples

  • NCT02016248 · 150 participants · NA

    SBRT Boost for Unfavorable Prostate Cancer'

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05280366, the US trial registry maintained by the National Library of Medicine. NCT05280366 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.